<DOC>
	<DOCNO>NCT01139775</DOCNO>
	<brief_summary>LY2603618 potent selective inhibitor deoxyribonucleic acid ( DNA ) damage checkpoint kinase 1 ( Chk1 ) . It develop chemotherapeutic-enhancing agent treatment cancer . Ongoing Phase 1 study show feasibility combine LY2603618 either gemcitabine pemetrexed . The objective study find dose LY2603618 safely combine standard dos pemetrexed cisplatin test triplet offer significant improvement progression-free survival participant Stage IV nonsquamous non-small cell lung cancer ( NSCLC ) first-line palliative treatment .</brief_summary>
	<brief_title>A Study Non Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Phase 1 portion : Participants cytologic histologic diagnosis nonsquamous Nonsmall Cell Lung Cancer ( NSCLC ) classify Stage IV accord seventh edition American Joint Committee Cancer ( AJCC ) classification combination pemetrexed cisplatin deem appropriate Participants histologic cytologic diagnosis malignant mesothelioma unresectable Participants histologic cytologic diagnosis advance metastatic solid tumor candidate standard therapy combination pemetrexed cisplatin deem appropriate Phase 2 portion : Have histological diagnosis NSCLC predominantly squamous cell histology classify Stage IV accord seventh edition American Joint Committee Cancer ( AJCC ) classification Be eligible first line palliative treatment platinum doublet Have archive tumor tissue ( cytology ) Phase 1 participant measurable nonmeasurable disease . Phase 2 participant must least 1 measurable lesion accord Investigational New Drug ( IND ) ( Response Evaluation Criteria Solid Tumors [ RECIST ] ) definition . Tumor lesion locate previously irradiate area consider measurable new show unequivocal progression . Have performance status less equal one Eastern Cooperative Oncology Group ( ECOG ) scale Have adequate hematologic , hepatic renal organ function Prior radiation therapy treatment cancer allow less 25 % bone marrow , participant must recover acute toxic effect treatment prior study enrollment . Prior radiation whole pelvis allow . Prior radiotherapy must complete least 4 week study entry For woman : Must surgically sterile , postmenopausal , compliant highly reliable contraceptive method ( failure rate le 1 % ) 6 month treatment period ; must negative serum urine pregnancy test within 7 day study enrollment must breastfeeding.For men : Must surgically sterile compliant contraceptive regimen 6 month treatment period Have serious preexist medical condition serious concomitant systemic disorder would compromise safety patient his/her ability complete study , discretion investigator ( example , unstable angina pectoris uncontrolled diabetes mellitus ) . Special attention pay kidney heart condition may worsen cisplatin treatment hydration Have central nervous system ( CNS ) metastases ( unless participant complete successful local therapy CNS metastases corticosteroid least 4 week start study therapy ) . A screening compute tomography ( CT ) scan magnetic resonance imaging ( MRI ) enrollment absence clinical suspicion brain metastasis require Have current active infection would , opinion investigator , compromise patient 's ability tolerate therapy Have know allergy pemetrexed , cisplatin , LY2603618 , ingredient pemetrexed , cisplatin , LY2603618 Have clinically significant ( physical exam ) thirdspace fluid collection ; example , ascites pleural effusion control drainage procedure prior study entry Patients take nonsteroidal antiinflammatory drug ( NSAIDs ) interrupt treatment appropriately accord guideline Have receive recent yellowfever vaccination ( within 28 day enrollment ) receive concurrent yellowfever vaccination Phase 1 portion : Have receive 2 previous line chemotherapy advanced/metastatic disease Have receive 6 cycle therapy contain alkylating agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>solid tumor</keyword>
	<keyword>Mesothelioma</keyword>
	<keyword>Carcinoma</keyword>
</DOC>